The news: The Telegraph reported on 23 June 2026 that the White House denied Donald Trump was given early compassionate-use access to retatrutide, an experimental obesity drug still in Eli Lilly trials. The story followed a report by the health-news site STAT that a “well connected” 79-year-old had been granted access; the White House strongly denied the applicant was the president. The detail worth holding onto: retatrutide is investigational, not approved before at least 2027, and Lilly itself says no one should take anything claiming to be retatrutide outside a Lilly-sponsored clinical trial.
This article summarises and comments on reporting by The Telegraph: Ben Stockton, “Trump denies taking super-strength obesity drug” (23 June 2026). Read the original for the full report. New-U is independent and not affiliated with The Telegraph; the link carries no endorsement either way.
The politics of the story will get the clicks; the pharmacology underneath it is the part that matters here. A drug that is years from approval was, according to the reporting, sought through an exceptional access pathway by someone “well connected” — which tells you everything about how far demand for the next obesity blockbuster has run ahead of the evidence and the regulator. Here is what the story says, and what it means for anyone looking at retatrutide as a research compound.
According to the Telegraph, the health-news website STAT reported that a 79-year-old applied in April to use retatrutide under the FDA’s compassionate-use programme, that senior health officials noted the applicant appeared to be “well connected”, and that the application was granted — to treat refractory obesity with obstructive sleep apnea and pulmonary hypertension. STAT speculated the applicant could be Trump, who turned 80 in June and has previously said he “probably should” take weight-loss drugs. After publication, White House officials strongly denied the president was the mystery applicant, with a senior deputy press secretary stating the application “was not for the President”. Trump’s May medical evaluation, the piece notes, did not mention the conditions cited in the application.
Retatrutide (colloquially “Red Tide” or “Triple G”) is an experimental obesity drug from Eli Lilly — the same company behind Zepbound and Mounjaro. Mechanistically it is a triple agonist, acting on the GIP, GLP-1 and glucagon receptors at once, and its early trial results have been described as a possible “game changer”, with weight-loss figures approaching those seen after bariatric surgery. It is in Phase 3 trials and, per the reporting, is not expected to be approved by the FDA until at least 2027. For the descriptive, research-framed background, see our retatrutide research guide and the Phase 3 TRIUMPH trial overview, plus how it sits beside semaglutide and tirzepatide in our GLP-1 comparison and the wider next obesity-research wave.
The FDA’s compassionate-use (expanded access) pathway exists for patients with a serious or immediately life-threatening condition to obtain an investigational product outside a trial when there is no comparable approved option. It is, by design, an exception — a narrow, individually-reviewed door, not a retail channel. The newsworthiness of the reported case is precisely that an exceptional route was reportedly used for a drug that is otherwise unavailable, which is what fuelled the speculation.
The line that matters. Eli Lilly states plainly that no one should take anything claiming to be retatrutide outside a Lilly-sponsored clinical trial. The drug has no marketing authorisation; for human use, the only legitimate route is a clinical trial or, exceptionally, expanded access. Research-use-only retatrutide is a different category entirely — reference material supplied to laboratories, labelled not for human consumption, with no dosing or therapeutic guidance. This page is general information, not legal or medical advice.
The Telegraph notes that demand is so high that people are reportedly seeking out retatrutide, with some clinics advertising access. That same demand, running years ahead of approval, is exactly what feeds the grey market a separate investigation documented in detail — anonymous online sellers, contaminated product, and the misuse of the “research use only” label as cover for human self-injection. We unpack that in our companion piece, The Unregulated Peptide Grey Market. The responsible position is the same in both: for a compound this early, the only thing a buyer can actually verify is identity and purity, through independent third-party testing and a Certificate of Analysis — and even verified material remains research-use-only, not for human consumption.
Did Trump take retatrutide?
The White House denies it; a senior deputy press secretary said the reported compassionate-use application “was not for the President”. (The Telegraph, 23 June 2026.)
Is retatrutide approved?
No. It is in Phase 3 trials and, per the reporting, is not expected to be FDA-approved until at least 2027.
Can you legitimately buy it for human use?
No. Eli Lilly says no one should take anything claiming to be retatrutide outside a Lilly-sponsored trial. Research-use-only material is a separate category, not for human consumption.
Primary source: The Telegraph, Ben Stockton, “Trump denies taking super-strength obesity drug” (23 June 2026). External links are provided for research reference only; New-U is not affiliated with these organisations and links carry no endorsement either way.
New-U Research Compounds supplies sealed 10-vial packs, independently verified by Janoshik and Freedom Diagnostics for >99% purity, with a Certificate of Analysis. Research use only - not for human consumption.
Browse the catalogAt New-U, we believe better conversations start with better information. For laboratory research use only. Not for human consumption.